Most Recent
AI pathology invention just administrative tool, not patentable: IP Australia
Intellectual Property 2024-11-21 11:03 pm By Sam Matthews

AI tech company Paige can’t patent a tool to provide quality control for analysis of pathology images, with IP Australia finding the invention is merely an “administrative scheme” to automate the role of human pathologists. 

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

Judge grounds Moccona’s infringement claims over Vittoria’s coffee jar design
Intellectual Property 2024-11-07 4:27 pm By Cindy Cameronne

Vittoria has defeated claims in an intellectual property battle that it infringed on rival Koninklijke Douwe Egbert’s trade mark for the design of its Moccona instant coffee jar.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

Element Zero appeals search order win for Fortescue in trade secrets case
Intellectual Property 2024-10-24 11:54 pm By Christine Caulfield

Green iron start-up Element Zero is continuing its fight over search orders won by rival Fortescue that it claimed were a massive over-reach.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

Coles dodges iFit challenge to Perform powerbar brand
Intellectual Property 2024-10-24 11:19 pm By Sam Matthews

Coles has defeated a trade mark challenge to its Perform brand of sports nutrition products by a sports equipment company.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

Bayer’s patents for blockbuster blood thinner Xarelto invalid: court
Intellectual Property 2024-10-23 11:45 pm By Sam Matthews

Bayer has lost its battle to protect top-selling blood thinner Xarelto from generic competition, with the Full Court finding two patents for the drug are invalid.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

Fortescue scores win against start-up accused of ‘industrial scale’ misuse
Intellectual Property 2024-10-04 3:03 pm By Cindy Cameronne

Fortescue has defeated a bid by its former CFO’s green iron start-up to set aside search orders that were said to have been secured “off the back of egregious material non-disclosure”.  

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

Biotech files new patent suit against Samsung Bioepis over Crohn’s drug
Intellectual Property 2024-09-26 11:55 pm By Sam Matthews

Samsung Bioepis can’t get indemnity costs from Janssen Biotech after it surrendered patents for Crohn’s disease drug Stelara and filed a fresh case based on new patents for the drug. 

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

Fortescue denies IP head told Element Zero founder to delete documents
Intellectual Property 2024-08-20 11:21 pm By Sam Matthews

Fortescue has rejected Element Zero’s “implausible” claims that the start-up’s founder was instructed by the mining giant’s IP manager to access and delete certain documents after his resignation, as it defends allegations that search orders it won over the alleged misappropriation of its confidential information were based on weak evidence.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

‘Industrial scale forensic debacle’: Element Zero blasts Fortescue search orders
Energy & Natural Resources 2024-08-19 10:06 pm By Sam Matthews

Start-up Element Zero has attacked search orders won by Fortescue over the alleged misappropriation of the mining company’s confidential information by three former employees, calling the orders an “industrial scale forensic debacle” won on weak evidence and the failure to disclose material information.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

GSK defeats Novadart trade mark for generic rival to prostate drug Avodart
Intellectual Property 2024-08-12 11:47 pm By Andy Sidler

A GlaxoSmithKline unit has defeated Nova Pharmaceuticals’ bid to trade mark ‘Novadart’ for a generic version of the British company’s market-leading drug prostate drug ‘Avodart’, with a delegate finding the mark would cause consumer confusion.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?